



## **A Review on Psoriasis: Types, Development, Mechanism And Precautions**

**Prajakta Patil, Pratiksha Padalkar, Bandu Pawar, Avinash Surwase and Amol Jadhav**

*Department of Microbiology, Yashwantrao Chavan Institute of Science (autonomous), Satara, Maharashtra, India-415001*

*\*Corresponding author- Bandu Pawar (Email Id- pawarbs1801@gmail.com)*

### **ABSTRACT**

*Psoriasis is a complex, long-term autoimmune inflammatory skin disease. It has a 2% catholic pervasiveness with a generality of around 4.6% in wealthy countries. It has links to several serious medical illnesses, such as depression, spondyloarthritis, heart disease, intestinal disorders, and brain infections (31 Oct 2021). In different atopic dermatitis and allergies and small regularly seen contrast to normal rates of development (12 Jan 2002). The disease has no cure, but we can give comfort to the patient with the help of treatment depending upon the type and gravity of psoriasis many therapeutic mediators are accessible for the treatment (2015). It is followed by phototherapy, ultraviolet light therapy, and anti-inflammatory and immunosuppressive drugs for more considerable conditions (1 Dec 2002). Treatment is laminated by disease severity and impact on quality of life.*

**Keywords:** *Psoriasis, Disease, inflammatory, patients, mediated.*

Received 12.11.2022

Revised 23.11.2022

Accepted 10.12.2022

### **INTRODUCTION**

Beginning in the early 19th century, Robert Willan recognized psoriasis as a recognized condition, and Ferdinand Hebra gave it a name in 1841 [1]. The English word "psoriasis" is a combination of the Greek words "Psora," which means to itch, and "iasis" which refers to a state [5]. Psoriasis is a chronic skin illness that has a hierarchy of clinical symptoms and a synergistic interplay between inherited, environmental, and immunological factors. With a global currency of 2%, the prevalence of psoriasis is higher in wealthy countries, at about 4.6 percent. Psoriasis has a major impact on all facets of quality of life, including the physical, psychological, social, sexual, and occupational elements [5]. An illness caused by T-cells is psoriasis [8]. Skin-associated lymphoid tissue (SALT) is a precursor of numerous immunological and epidermal components [7]. The entire body can develop psoriasis, including the eyelids, ears, lips, skin, folds, hands, feet, nails, etc. 29 October is celebrated as world psoriasis day and it is important to the betterment of psoriatic patients [10].

### **EPIDEMIOLOGY:**

Psoriasis can affect both men and women, however, it typically first appears in women and those with familial history [4]. It can arise at any time and has been seen at both births and in elderly people. Between the ages of 15 and 20 is when psoriasis frequently first appears, and between the ages of 55 and 60 is when it returns [11]. Diabetes and myocardial infarction risk were modestly greater in those with severe psoriasis (Koch et al., 2015) [12]

### **Clinical presentation:**

Psoriasis manifests itself in several ways: plaque, flexural, guttate, pustular, or erythrodermic psoriasis.

**Plaque psoriasis:** The most common variety of psoriasis is this one. Anywhere between 58 and 97 percent of patients are impacted [11]. Inflammatory red, raised, dry plaques with sharp borders that are different diameters and typically covered in silvery or white scales (figure 1). It comprises the mastoid and the scalp. Extensor surfaces of the hands, knees, elbows, face, palm, soles, and nails as well as the trunk [9].



**Figure1: Plaque psoriasis [20]**

**Flexural psoriasis:** Intertriginous psoriasis is another name for it. affected anywhere between 12 and 26% of all patients. Scaleless, bright red or white, horizontally defined, wet patches or plaques are what flexural lesions look like; they typically lack scales. axillae, antecubital fossae, inflammatory creases, umbilicus, groins, genital areas, gluteal cleft, popliteal fossae, and other body folds are among the virtually mainly flexural body sites affected (figure 2) [9].




**Figure 2: Flexural psoriasis [21]**

**Guttate psoriasis:** A little patchy appearance. occurs most frequently in childhood and adolescence and affects between 0.6 percent and 20 percent of those with psoriasis. Reddish, drop-like papules and plaques with guttate psoriasis (figure 3) mostly affect the trunk, arms, and legs. Streptococcus infection of the upper respiratory tract and previous skin signs are linked to the onset [9].



**Figure3: Guttate Psoriasis [22]**

**Pustular psoriasis:** Of all cases of non-infected, pus-filled psoriasis, it affects between 1.1 percent and 12 percent of people. Expanding pustules involves only a small area, such as the soles of the feet or the palms of the hands (figure 4), or it may affect the entire body surface after a trigger [9].



**Figure 4: Pustular psoriasis [23]**

**Erythrodermic psoriasis:** 0.4–7% of all psoriasis patients are affected by this condition. Most of the body's surface has a fiery redness and has been exfoliated (figure 5). The worst variety of psoriasis, capable of resulting in hypothermia, hypoalbuminemia, and high-output heart failure [9].



**Figure 5: Erythrodermic psoriasis [24]**

**DEVELOPMENT:**

Psoriasis arises when skin cells reproduce more fast than usual. Although the precise cause of this is uncertain, research suggests that an immune system problem is probably to blame. Your body creates fresh skin cells in the base of the skin [19]. These skin cells gradually move through the layers of the skin until they reach the outermost layer, where they die and separate (figure 6). The entire procedure typically takes 3 to 4 weeks. Patients with psoriasis, however, only need 3 to 7 days to complete this reatment. As a result, immature cells quickly build up on the skin's surface, resulting in rough areas covered with scales [12].




Figure6: Development of scales [25]

**MECHANISM:**

Theoretically, an unknown antigen initiates T-cell activation, which results in the release of several cytokines by keratinocytes, inflammatory cells, and activated T cells. The psoriasis-specific lesion is brought on by the keratinocyte's hyperproliferation. Before becoming activated, live T cells must go through a multi-step process that involves contact with different cell types. The inflammatory process begins when an antigen in the skin stimulates a dendritic cell or another antigen-presenting cell. In a process involving antigen presentation, the dendritic cell interacts with the T cell as it travels to the lymph nodes. T cell proliferation and migration through to the circulation site of the inflammation in the skin during this phase involve cells through the bloodstream and molecules such as CAM after T cell to the skin. Another immune component such as cytokine plays an important role in the inflammatory cascade this chemical changes T cells into activated memory T cells because it remembers the antigen. Additionally, the cytokines interleukins 12 and 23 are generated by dendritic cells and help to activate T cells, which are a part of the inflammatory process and lead to keratinocyte hyperproliferation and the development of psoriasis plaque (figure 6). According to our understanding of immunopathogenesis, while there is no known cure for psoriasis, it has become more prevalent in recent years [15].




Figure7: Mechanism of forming scales [26]

**Treatment:**

Treatment will vary depending on the type and severity of the ailment if a doctor determines that a patient has psoriasis. Medication and counseling are the two primary possibilities. Corticosteroids, analogs of vitamin D, anthralin (Dithraol), coal tar, retinoids, methotrexate, cyclosporine, phototherapy, light therapy, anti-inflammatory medications, and immunosuppressive drugs are current psoriasis treatments [17]

## PRECAUTIONS:

- 1) Patients' application of moisturizing creams.
- 2) Avoid traveling when it's cold and dry outside.
- 3) Drugs that cause flare-ups should also be avoided by patients.
- 4) Avoid getting wounds, scratches, bumps, and infections.
- 5) The toughest individuals require some sunlight, but not too much.
- 6) Decrease anxiety.
- 7) To reduce stress, engage in yoga, physical activity, and meditation.
- 8) Consume a balanced diet.
- 9) Recognizing food triggers and avoiding them
- 10) Patients should refrain from using tobacco or alcohol in excess [18].

**New drug targets:** A crucial regulator of psoriatic inflammation is HSP90, which is produced by keratinocytes and mast cells. In the management of psoriasis, dithranol is quite successful [14, 16].

## CONCLUSION

A common skin condition that irritates, psoriasis is primarily genetically determined and associated with serious chronic medical and psychiatric conditions. It can manifest itself across a large clinical spectrum. For long-term recovery, prompt therapy is crucial as psoriasis is linked to several serious medical and psychological conditions.

## REFERENCES:

1. Di Meglio P, Villanova F, Nestle FO. (2014). Psoriasis. *Cold Spring Harb Perspect Med.* 1;4(8):a015354. doi: 10.1101/cshperspect.a015354. PMID: 25085957; PMCID: PMC4109580.
2. Rendon A, Schäkel K. (2019). Psoriasis Pathogenesis and Treatment. *Int J Mol Sci.* 2019;20(6):1475. Published. doi:10.3390/ijms20061475
3. Bulat V, Šitum M, Delaš Aždajić M, Lovrić I, Dediol I. (2020). Study on the Impact of Psoriasis on Quality of Life: Psychological, Social and Financial Implications. *Psychiatr Danub.* 32(Suppl 4):553-561. PMID: 33212463.
4. AMA Raharja A, Mahil SK, Barker JN. (2021). Psoriasis: a brief overview. *Clin Med (Lond).* 221(3):170-173. doi:10.7861/clinmed.2021-0257
5. Dutta, Siddhartha & Chawla, Shalini & Kumar, Sahil. (2018). Psoriasis: A Review of Existing Therapies and Recent Advances in Treatment. 4. 2018.
6. <https://jddonline.com/articles/a-phase-3-randomized-trial-demonstrating-the-improved-efficacy-and-patient-acceptability-of-fixed-dose-S1545961621P0420X>
7. Kim J, Bissonnette R, Lee J, Correa da Rosa J, Suárez-Fariñas M, Lowes MA, Krueger JG. The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but with Key Differences in Immune Regulatory Genes. *J Invest Dermatol.* 2016 Nov;136(11):2173-2182. doi: 10.1016/j.jid.2016.04.032. Epub 2016 May 13. PMID: 27185339.
8. Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. Immunopathogenic mechanisms in psoriasis. *Clin Exp Immunol.* 2004 Jan;135(1):1-8. doi: 10.1111/j.1365-2249.2004.02310.x. PMID: 14678257; PMCID: PMC1808928.
9. World Health Organization. (2016). Global report on psoriasis. World Health Organization. <https://apps.who.int/iris/handle/10665/204417>
10. <https://nationaltoday.com/world-psoriasis-day/>
11. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. *Ann Rheum Dis.* 2005 Mar;64 Suppl 2(Suppl 2):ii18-23; discussion
12. Hwang ST, Nijsten T, Elder JT. Recent Highlights in Psoriasis Research. *J Invest Dermatol.* 2017 Mar;137(3):550-556. doi: 10.1016/j.jid.2016.11.007. Epub 2017 Jan 4. PMID: 28063651.
13. <https://www.nhs.uk/conditions/psoriasis/causes/>
14. Kakeda M, Arock M, Schlapbach C, Yawalkar N. Increased expression of heat shock protein 90 in keratinocytes and mast cells in patients with psoriasis. *J Am Acad Dermatol.* 2014 Apr;70(4):683-690.e1. doi: 10.1016/j.jaad.2013.12.002. Epub 2014 Feb 9. PMID: 24521827.
15. Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. Immunopathogenic mechanisms in psoriasis. *Clin Exp Immunol.* 2004 Jan;135(1):1-8. doi: 10.1111/j.1365-2249.2004.02310.x. PMID: 14678257; PMCID: PMC1808928.
16. Kemény L, Ruzicka T, Braun-Falco O. Dithranol: a review of the mechanism of action in the treatment of psoriasis Vulgaris. *Skin Pharmacol.* 1990;3(1):1-20. doi: 10.1159/000210836. PMID: 2202336.
17. <https://www.cdc.gov/psoriasis/index.htm>
18. <https://www.webmd.com/skin-problems-and-treatments/psoriasis/understanding-psoriasis-basics>
19. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)32549-6/fulltext20](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32549-6/fulltext20).
20. <https://images.app.goo.gl/m8ujMoZfcCfydQU7>
21. <https://images.app.goo.gl/yiMfxgor9yBFrrve9>

22. [https://www.google.com/imgres?imgurl=https%3A%2F%2Fwww.frontiersin.org%2Ffiles%2FArticles%2F543944%2Ffmed-07-543944-HTML%2Fimage\\_m%2Ffmed-07-543944-g002.jpg&imgrefurl=https%3A%2F%2Fwww.frontiersin.org%2Farticles%2F10.3389%2Ffmed.2020.543944%2Ffull&docid=Jn\\_9BslzYyJ7aM&tbnid=CDdrCTk4aHEzdM&vet=1&source=sh%2Fx%2Fim](https://www.google.com/imgres?imgurl=https%3A%2F%2Fwww.frontiersin.org%2Ffiles%2FArticles%2F543944%2Ffmed-07-543944-HTML%2Fimage_m%2Ffmed-07-543944-g002.jpg&imgrefurl=https%3A%2F%2Fwww.frontiersin.org%2Farticles%2F10.3389%2Ffmed.2020.543944%2Ffull&docid=Jn_9BslzYyJ7aM&tbnid=CDdrCTk4aHEzdM&vet=1&source=sh%2Fx%2Fim)
23. <https://images.app.goo.gl/pqhw26A5huZq1jDJA>
24. <https://images.app.goo.gl/6N5FaukkSPCwjuqXA>
25. <https://images.app.goo.gl/djH3DPkAifMfoP3T6>
26. <https://www.google.com/imgres?imgurl=https%3A%2F%2Flaw.asia%2Fwp-content%2Fuploads%2F2022%2F08%2FDraft-drugs-devices-bill-released-for-feedback-L.jpg&imgrefurl=https%3A%2F%2Flaw.asia%2Fdraft-drugs-devices-bill-released-feedback%2F&docid=1rERNsiWB4IjkM&tbnid=sBxTeQkePEfXPM&vet=1&source=sh%2Fx%2Fim>

#### CITATION OF THIS ARTICLE

P. Patil, P. Padalkar, B. Pawar, A. Surwase and Amol Jadhav: A Review On Psoriasis: Types, Development, Mechanism And Precautions. Bull. Env.Pharmacol. Life Sci., Spl Issue [1]: 2023:87-92.